Brought to you by 
Biosimilars start-up Coherus BioSciences nets $79mm in Nasdaq IPO
10 Nov 2014
Executive Summary
Cancer and inflammatory diseases biosimilars start-up Coherus BioSciences Inc. netted $79mm in its initial public offering of 6.3mm shares at $13.50, the mid-point of its anticipated $12-15 range.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biosimilars start-up Coherus BioSciences nets $79mm in Nasdaq IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice